Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Metagenomi, Inc. due to alleged violations of federal securities laws related to misleading statements about its collaboration with Moderna, which has led to significant investor losses [1][2]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Metagenomi between February 9, 2024, and September 26, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Metagenomi, with a deadline of November 25, 2024, for investors to seek the role of lead plaintiff [1][4]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [1]. Group 2: Allegations Against Metagenomi - The complaint alleges that Metagenomi and its executives made false and misleading statements regarding their collaboration with Moderna, which was a key aspect of their business model [2]. - Metagenomi's initial public offering took place on February 13, 2024, selling 6.25 million shares at $15 per share [3]. - The collaboration with Moderna was terminated on May 1, 2024, leading to a significant drop in Metagenomi's stock price from $7.04 to $6.17 per share within a day [3]. Group 3: Investor Participation and Information - The lead plaintiff in the class action is defined as the investor with the largest financial interest who is typical of class members [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Metagenomi's conduct [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [3] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [3] Group 2: Legal Proceedings - A class action lawsuit has been filed against Metagenomi following the announcement on May 1, 2024, that the collaboration agreement with Moderna was mutually terminated [3] - Investors are encouraged to join the class action, with a lead plaintiff deadline set for November 25, 2024 [1][4] Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [2] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [2]

Core Viewpoint - A securities class action lawsuit has been filed against Metagenomi Inc. for allegedly misleading investors regarding its prospects and relationship with Moderna during the class period from February 6, 2024, to September 26, 2024 [1][3]. Company Overview - Metagenomi Inc. is described as a "genetic medicines company" based in Emeryville, CA, with a significant partnership with Moderna, a leading Covid-19 vaccine company [2]. - The collaboration with Moderna included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple four-year research programs and subsequent licensed product agreements [2]. Key Events - On May 1, 2024, Metagenomi announced the mutual termination of its collaboration agreement with Moderna, which analysts noted was critical to Metagenomi's business model [3]. - Following the announcement, Metagenomi's share price dropped from $7.04 per share to $6.17 per share within a day, continuing to decline to slightly above $2.00 per share at the time of the lawsuit filing [3]. Legal Proceedings - Investors who purchased Metagenomi securities during the class period can seek to be appointed as lead plaintiff representatives by November 25, 2024 [2][4]. - The lawsuit claims that Metagenomi and its senior executives misled investors about the company's future prospects and its relationship with Moderna [3].

Lawsuit Overview - A class action lawsuit has been filed against Metagenomi Inc on behalf of investors who acquired its securities between February 9 2024 and May 1 2024 [1] - Investors have until November 25 2024 to apply to be appointed as lead plaintiff in the lawsuit [1] IPO and Stock Performance - Metagenomi conducted its IPO on February 12 2024 selling approximately 6 25 million shares at $15 per share [1] - On May 1 2024 Metagenomi announced the termination of its collaboration with Moderna leading to a 12 4% decline in share price from $7 04 to $6 17 [1] Allegations in the Lawsuit - The lawsuit alleges that Metagenomi's IPO registration statements were false and/or materially misleading [2] - Metagenomi represented itself as having a long-standing business relationship with Moderna but the collaboration was terminated shortly after the IPO [2] Law Firm Information - Kirby McInerney LLP is handling the lawsuit and has a history of recovering billions of dollars for shareholders in securities litigation [3]

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=108714&from=4 CLASS PERIOD: This lawsuit is on beha ...

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased stock pursuant to and/or traceable to Metagenomi Inc.'s (NASDAQ: MGX) registration statement for the initial public offering (IPO) held between February 9 and 13, 2024. Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. For more information, ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=108485&from=3 CLASS PERIOD: This lawsuit is on ...

PHILADELPHIA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Metagenomi Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the "Class Period"). Investors that suffered losses from METAGENOMI (NASDAQ: MGX) investments can follow the link below for more information regarding the lawsuit: CLICK HERE to learn more abo ...

Poster presentation highlights SMART adenine base editors (ABEs) small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing for therapeutically-relevant genome editing EMERYVILLE, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a poster titled "Engineering ...

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=107873&from=4 CLASS PERIOD: This lawsuit is on beha ...